

Special Issue

Advances in Human Monkeypox Vaccines Effectiveness, Safety and Hesitancy

Message from the Guest Editor

The human monkeypox (HMPX) outbreak of 2022 did not only cause several thousands of cases in non-endemic countries but also triggered multi-faceted debates about epidemic preparedness, discontinuation of smallpox vaccination, effectiveness and safety of the repurposed smallpox vaccines and drugs, and public interest in (acceptance of) immunization against orthopoxviruses. I am pleased to invite you to participate in this Special Issue which aims to delve into three main thematic areas. Firstly, the effectiveness of the repurposed smallpox vaccines that are used as pre- or post-exposure prophylaxis needs to be evaluated within the context of the ongoing outbreak, especially among high-risk groups and healthcare settings. Secondly, pre- and post-authorization safety of HMPX vaccines and antivirals should be actively monitored in order to update the current immunization guidelines in light of the best available evidence. Thirdly, vaccination acceptance and misconceptions among healthcare professionals, students, and high-risk groups are of utmost importance amid this outbreak because they may either accelerate or unnecessarily delay the task of epidemic control.

Guest Editor

Dr. Abanoub Riad

1. Masaryk Centre for Global Health (MCGH), Department of Public Health, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic
2. Department of Public Health, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic

Deadline for manuscript submissions

closed (20 October 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/146082

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).